Key Dates

Related Announcements

• April 24, 2024 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) – See PA-24-175
• April 24, 2024 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) - See PA-24-176
• April 24, 2024 - Mentored Research Scientist Development Award (Parent K01 - Independent Basic Experimental Studies with Humans Required) – See PA-24-177
• April 24, 2024 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) – See PA-24-181 
• April 24, 2024 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) – See PA-24-182 
• April 24, 2024 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required) - See PA-24-183
• April 24, 2024 - NIH Pathway to Independence Award (Parent K99/R00 – Independent Clinical Trial Required) - See PA-24-193
• April 24, 2024 - NIH Pathway to Independence Award (Parent K99/R00 – Independent Clinical Trial Not Allowed) – See PA-24-194
• April 24, 2024 - NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required) - See PA-24-195
• September 29, 2023 - Cancer Research Education Grants Program – Courses for Skills Development (R25 Clinical Trial Not Allowed) – See PAR-23-276
• September 29, 2023 - Cancer Research Education Grants Program – Research Experiences (R25 Clinical Trial Not Allowed) – See PAR-23-277
• September 29, 2023 - Cancer Research Education Grants Program – Curriculum or Methods Development (R25 Clinical Trial Not Allowed) – See PAR-23-278

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants of NCI’s interest in receiving Career Development Award applications from early career scientists conducting global cancer research.  

Background 

In the United States, incidence rates for all cancer sites have decreased on average by 1.1% each year over the last 10 years, but significant disparities persist in cancer incidence and mortality among certain racial and ethnic minorities and immigrant communities. The primary drivers for some of these disparities – exposure to risk factors, gaps in early detection, presence of co-morbidities, poor access to treatment services, and social determinants of health – also underlie the high cancer-related morbidity and mortality seen in low-and middle-income countries (LMICs), as defined by the World Bank. By 2030, 75% of the projected 21 million new cancer cases and 13 million annual cancer deaths worldwide will disproportionately occur in LMICs, where, in addition to the drivers noted above, genetic susceptibilities and cultural practices may also play a significant role in cancer risk. Cancer death rates are higher in these countries than for AIDS, tuberculosis, and malaria combined. These statistics reflect key trends in LMICs, including aging populations, the epidemiologic transition to more non-communicable diseases than infectious diseases, and environmental and lifestyle changes. To address this growing burden, there is an urgent need to recruit  a diverse workforce that is highly skilled and committed to generating context-specific evidence in LMICs that informs cancer prevention and control efforts. It is, therefore, important to  support early career investigators committed to careers in global cancer research as they develop skills and competencies, work with mentors, and transition into independent research careers. These deliberate attempts are needed to strengthen research capacity, including the development of relevant skills to tackle the multifaceted nature of cancers and foster equity in global research collaborations.  

Research Objectives 

The National Cancer Institute (NCI) Center for Global Health (CGH) is interested in applications from individuals committed to an independent career in global cancer research who propose mentored research projects in topics relevant to the LMIC where the research will be conducted. NCI is also interested in applications from established investigators committed to global cancer research education in LMICs.  Topics of interest include but are not limited to, studies in cancer biology and genetics, cancer epidemiology, research in cancer primary and secondary prevention, clinical and translational research, implementation science and health systems research, health disparities, health surveillance, and cancer informatics research, studies in integrative oncology and cancer survivorship as well as investigations that employ technology (including mHealth and eHealth) to address cancer control. As relevant, the proposed career development, research education, and/or mentoring project must be aligned with cancer control priorities in the LMIC. 

Application and Submission Information

This notice applies to Application Due Dates on or after October 12, 2024, and subsequent Application Due Dates through the expiration date of this NOSI (January 8, 2027). 

Applicants are strongly advised to check/verify the Application Due Date matrix listed in each of the notices of funding opportunity (NOFOs) listed below before applying.

Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice.

All instructions in the How to Apply - Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-CA-24-098” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Please check Section VII of the listed notices of funding opportunity (NOFOs). 

(For applications related to the Center for Global Health research interests)

Fatou Jallow, PhD
National Cancer Institute (NCI)  
Telephone: 240-620-0808
Email: [email protected]   

Sudha Sivaram, DrPH
National Cancer Institute (NCI)
Telephone: 240-276-5804
Email: [email protected]

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]